Tier 1 — highest

Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Maria-Corina Serban, Amirhossein Sahebkar, Alberto Zanchetti, Dimitri P Mikhailidis, George Howard, Diana Antal, Florina Andrica, Ali Ahmed, Wilbert S Aronow, Paul Muntner, Gregory Y H Lip, Ian Graham, Nathan Wong, Jacek Rysz, Maciej Banach, Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) Group
Journal of the American Heart Association 2016 5(7):e002713

Bibliography

PubMed
PMID 27405810
PubMed Central
PMC5015358
DOI
10.1161/JAHA.115.002713
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignSystematic review and meta-analysis of randomized trials
ModelHuman evidence synthesis
Sample7 trials; 587 participants
InterventionQuercetin supplementation
DurationSearches through January 31, 2015
EndpointsBlood pressure

What the study showed, in plain terms

Published in 2016, this source examined cardiovascular and metabolic health. Its evidence base was 7 trials; 587 participants. It evaluated Quercetin supplementation across Searches through January 31, 2015.

Systolic and diastolic pressure decreased modestly in pooled estimates.

Indirect comparisons did not establish a significant difference between dose categories. The study cannot define a proven dose threshold or demonstrate cardiovascular event reduction.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Systolic and diastolic pressure decreased modestly in pooled estimates.
  • The recorded outcome domains were Blood pressure.
  • This synthesis reuses the included study populations; it is not an additional randomized participant cohort.

What this study can and cannot tell us

  • Indirect comparisons did not establish a significant difference between dose categories. The study cannot define a proven dose threshold or demonstrate cardiovascular event reduction.
  • Pooled estimates depend on the included trials and may share participants with companion publications or other reviews. A statistically significant surrogate outcome does not establish disease prevention.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 1
The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials
Reza Tabrizi et al. · Critical reviews in food science and nutrition · 2020

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology